Bacopa Monnieri
Bacopa monnieri
Ayurvedic herb for memory — but it takes weeks.
Evidence tier
Moderate
Research weight
Citations
20 verified / 20
Classification
Ayurvedic
❝
What the evidence says. Several controlled trials; effects real but modest or context-dependent.
What is Bacopa Monnieri?
Bacopa Monnieri (Bacopa monnieri) is an Ayurvedic herb used for memory formation. NutriDex grades the human evidence as Moderate. Bacopa is an Ayurvedic nootropic with antioxidant and dendrite-promoting effects. Multiple RCTs show improved memory acquisition and retention, though benefits emerge slowly over 8–12 weeks rather than acutely. Effects are reliable but modest. It does not work as an immediate 'study aid'.
Purported Benefits
✓Memory formation
✓Learning speed
✓Reduced anxiety
✓Attention
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Memory formation & retentionOlder meta-analyses and some RCTs show improved delayed recall, but recent network meta-analyses rank it near chance and a 2025 RCT found no benefit. | Mixed | ↔ mixed · small | 5 |
| Speed of attention / processingMeta-analysis of 9 RCTs (>=12 weeks) found shortened Trail B and choice reaction time, indicating improved attention speed; low risk of bias. | Moderate | ↑ benefit · small | 2 |
| Learning speedEffects emerge slowly over 8-12 weeks rather than acutely; supportive RCTs are small and benefit is modest, not an immediate study aid. | Preliminary | ↑ benefit · small | 2 |
| Anxiety / stress reductionSeveral RCTs report reduced self-reported stress, fatigue and stress biomarkers, though often as secondary outcomes when cognitive endpoints were null. | Preliminary | ↑ benefit · small | 3 |
| Cognition in MCI/dementiaOne small MCI RCT improved MoCA, but a systematic review of 5 Alzheimer's RCTs found no difference vs placebo or donepezil on very-low-certainty evidence. | Preliminary | ↔ mixed | 2 |
Dosing & Compounds
Typical Dose
300 mg/day standardized to ~50% bacosides; effects build over 8–12 weeks.
Active Compounds
Safety & Cautions
Generally safe. Common GI upset (take with food). May increase thyroid hormone; caution with thyroid meds. Educational only — always check with your doctor or pharmacist before combining Bacopa Monnieri with any medicine.
Key Studies ★ 20 studies
Meta-analysis
Wang 2026 (network meta-analysis)
✓ PubMed
Network meta-analysis of 25 RCTs (1,861 healthy older adults) ranked Bacopa monnieri highest for executive function (SUCRA 91.3%) and language, with a significant learning/memory benefit versus placebo (MD 0.49, 95% CI 0.07-0.90).
Systematic review
Valotto Neto 2024 (systematic review)
✓ PubMed
Systematic review of 22 clinical trials concluded Bacopa monnieri can enhance cognition, emotional function and reduce inflammatory/oxidative markers, supporting it as a complementary approach in neurodegenerative conditions.
Meta-analysis
Feng 2026
✓ Full text
Network meta-analysis of RCTs in healthy older adults found Bacopa monnieri significantly improved learning and memory versus placebo (MD = 0.49, 95% CI 0.07–0.90); the Bacopa compound ranked first for language and high for executive function.
Meta-analysis
Wang 2025
✓ Full text
Network meta-analysis of 27 RCTs (2,334 participants) in healthy adults ranked Bacopa monnieri extract 10th for memory (SUCRA 50.7%, near chance) with no significant superiority over placebo for primary cognitive outcomes.
Systematic review
Valotto Neto 2024
✓ Full text
Systematic review of 22 clinical trials concluded Bacopa monnieri improves memory retention, processing speed and attention, attributing effects to reduced oxidative stress and NF-kB-mediated inflammation.
Systematic review
Cave et al. 2023
✓ PubMed
Systematic review of 21 RCTs of herbal/nutritional medicines in older adults with/without subjective cognitive impairment; Bacopa monnieri was among the most-studied (6/21 trials). 14/21 studies reported improvement in >=1 cognitive domain, but 14/21 had high methodological risk of bias, yielding overall low-quality evidence for efficacy.
Systematic review
Basheer 2022 (systematic review)
✓ PubMed
Systematic review of 5 RCTs found no difference between Bacopa monnieri and placebo or donepezil for Alzheimer's dementia on very-low-certainty evidence, with no major safety concerns; larger rigorous trials are needed.
Systematic review
Basheer 2022
✓ Full text
Systematic review of 5 RCTs found no difference between Bacopa monnieri and placebo or donepezil for treating Alzheimer dementia, based on very low certainty evidence (high risk of bias, small samples).
agency safety review
LiverTox 2024 (NIH safety review)
✓ Full text
NIH LiverTox monograph (updated 2024) assigns Bacopa monnieri a likelihood score of E (unlikely cause of clinically apparent liver injury), noting that despite widespread use it has not been linked to serum enzyme elevations or hepatotoxicity in large drug-induced liver injury registries.
Meta-analysis
Pase 2012 meta-analysis
✓ PubMed
Consistent improvement in delayed word-recall memory.
Meta-analysis
Kongkeaw et al. 2014
✓ PubMed
Meta-analysis of 9 RCTs (518 subjects; 437 analyzed) of standardized Bacopa monnieri extract (300-450 mg/day, >=12 weeks). Significant improvement in cognition: shortened Trail B test (-17.9 ms; 95% CI -24.6 to -11.2; p<0.001) and decreased choice reaction time (-10.6 ms; 95% CI -12.1 to -9.2; p<0.001), indicating improved speed of attention. Low risk of bias.
RCT
Lopresti 2025 (RCT, Bacumen)
✓ PubMed
In 101 adults aged 40-70 with self-reported memory/attention problems, 300 mg/day Bacopa for 12 weeks did not improve verbal learning, attention or working memory versus placebo, but reduced self-reported stress reactivity and fatigue.
RCT
Mahmoudi 2024 (RCT)
✓ PubMed
Triple-blind RCT in 62 patients with mild cognitive impairment found 160 mg/day Bacopa monnieri for 2 months improved overall cognitive performance (MoCA) but had no effect on sleep quality versus placebo.
RCT
Eraiah 2024
✓ Full text
12-week double-blind RCT in 80 healthy adults found 300 mg/day Bacopa extract (90 mg bacosides) significantly improved verbal, spatial, working and episodic memory versus placebo, with decreased serum cortisol and increased BDNF by day 84.
RCT
Lopresti 2021 (RCT, Bacognize)
✓ Full text
28-day RCT in 100 adults with poor sleep found Bacopa (150 mg twice daily) did not improve insomnia versus placebo but was associated with greater improvements in emotional wellbeing, general health and reduced stress biomarkers (salivary alpha-amylase, sIgA).
authoritative reference / safety review
Mishra 2023 (StatPearls)
✓ Full text
StatPearls reference (updated 2023) concludes Bacopa monnieri has a high therapeutic index with no demonstrated human toxicity; the most common adverse effects are gastrointestinal (increased stool frequency, nausea, abdominal cramps), and standardized extract dosing is 300-450 mg/day (24-55% bacosides).
RCT
Downey et al. (Stough group) 2013
✓ PubMed
Acute double-blind, placebo-controlled crossover RCT in 24 healthy adults of Bacopa special extract CDRI 08 (KeenMind). The 320 mg dose improved Cognitive Demand Battery performance at the 1st, 2nd, and 4th post-dose repetitions vs placebo, with no adverse cardiovascular effects; demonstrates an acute (not only chronic) cognitive benefit.
narrative review
Gosciniak 2025 (Nutrients review)
✓ PubMed
Narrative review in Nutrients (2025) of preclinical and clinical evidence concludes Bacopa monnieri exerts neuroactive, memory-enhancing effects and is generally non-toxic with no serious adverse events, while highlighting poor oral bioavailability of bacosides and contraindications such as hyperthyroidism and pregnancy.
Study
Stough 2001
✓ PubMed
Improved retention of new information after 12 weeks.
Study
Calabrese 2008
✓ PubMed
Enhanced memory and reduced anxiety in older adults.